Growth Hormone Deficiency Market: Opportunity Analysis and Forecast to 2024

"The Latest Research Report OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecast to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Growth Hormone Deficiency Market

GlobalData estimates the 2014 sales for growth hormone deficiency (GHD) at approximately $1.26 billion across the 7MM covered in this report. The market will grow moderately at a CAGR of 4.08% during the 10-year forecast period, generating sales of approximately $1.88 billion at the end of 2024. The US market is expected to grow the fastest of the three regions, recording a CAGR of 4.88% and generating around 59% of global sales in 2024. The major driver for this growth across the 7MM will be the launch of long-acting biobetter growth hormones (GH), which will rapidly take away shares from the currently marketed daily injectable growth hormones.

Highlights

Key Questions Answered

- Overall, the greatest unmet need in the GHD space is the issue with treatment adherence and compliance. There are other prominent unmet needs highlighted by the Key Opinion Leaders (KOLs). What are these? Will the pipeline drugs fulfil these unmet needs of the market?
- The 10-year forecast period will mark the launch of six pipeline long-acting GH drugs. How will the sales of the existing drugs be impacted? Which of the pipeline drugs will have the highest peak sales at the highest CAGR, and why?
- What are the roles of payers in this highly competitive disease space? How does this affect market shares of the GH brands, especially in the US? What are the chances of reimbursement for the long-acting GH drugs in pipeline?

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/443290

Key Findings

- The major driver for growth in the GHD market during the forecast period will be the launch of six long-acting GH biobetters with less frequent dosing regimens. These will not only boost the use of GH, but will in addition increase adherence and compliance in patients.
- KOLs interviewed by GlobalData opined that these long-acting biobetters will eventually replace most of the patient shares of currently marketed GH drugs during the forecast period.
- In other interviews, US payers revealed to GlobalData the current trend of GH manufacturers negotiating with insurance companies as a means of gaining market access for their particular brand.
- Low disease awareness and stringent regulatory policies lead to sub-optimal dosing and treatment outcomes in the Japanese market.
- Companies in the early-stage GHD space demonstrate two major trends development of long-acting GH formulations and innovation in GH delivery strategies.

Scope

- Overview of GHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized GHD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GHD therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global GHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

View Report @ https://www.marketresearchreports.biz/reports/443290/opportunityanalyzer-growth-hormone-deficiency-opportunity-analysis-and-forecast-to-2024-market-research-reports

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the GHD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GHD therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the 7MM GHD therapeutics market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 17
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 18
3 Disease Overview 19
3.1 Etiology and Pathophysiology 19
3.1.1 Etiology 19
3.1.2 Pathophysiology 20
3.2 Symptoms 22
3.3 Diagnosis 22
3.4 Prognosis 23
3.5 Quality of Life 23

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/443290

4 Epidemiology 25
4.1 Disease Background 25
4.1.1 GHD in Children 25
4.1.2 GHD in Adults 26
4.2 Risk Factors and Comorbidities 26
4.3 Global Trends 28
4.3.1 GHD in Children 29
4.3.2 GHD in Adults 31
4.4 Forecast Methodology 32
4.4.1 Sources Used 36
4.4.1.1 7MM 36
4.4.1.2 Diagnosed Cases of GHD in Children 37
4.4.1.3 Diagnosed Cases of GHD in Adults 38
4.4.1.4 GHD Etiological Classification in Children 38
4.4.1.5 GHD Etiological Classification in Adults 39
4.4.2 Sources Not Used 40
4.4.3 Forecast Assumptions and Methods 41
4.4.3.1 Temporal Trends 41
4.4.3.2 Sex-Specific Trends 41
4.4.3.3 Diagnosed Prevalent Cases of GHD in Children 41
4.4.3.4 Diagnosed Prevalent Cases of GHD in Adults 42
4.4.3.5 GHD Etiological Classification in Children 43
4.4.3.6 GHD Etiological Classification in Adults 43
4.5 Epidemiological Forecast of GHD (2014-2024) 44
4.5.1 Diagnosed Prevalent Cases of GHD 44
4.5.2 Diagnosed Prevalent Cases of GHD by Sex 46
4.5.3 Diagnosed Prevalent Cases of GHD by Age 47
4.5.3.1 Diagnosed Prevalent Cases of GHD in Children 47
4.5.3.2 Diagnosed Prevalent Cases of GHD in Adults 49
4.5.4 Age-Adjusted Diagnosed Prevalence of GHD 50
4.5.5 Diagnosed Prevalent Cases of GHD in Children by Etiological Classification 51
4.5.6 Diagnosed Prevalent Cases of GHD in Adults by Etiological Classification 52
4.6 Discussion 53
4.6.1 Epidemiological Forecast Insight 53
4.6.2 Limitations of the Analysis 54
4.6.3 Strengths of the Analysis 55
5 Competitive Assessment 56
5.1 Overview 56
5.2 Treatment Algorithm 56
5.3 Market Access, Reimbursement, and Clinical Practice 58
5.4 Product Profiles Recombinant Human Growth Hormones 60
5.4.1 Overview 60
5.4.1.1 Genotropin 61
5.4.1.2 Humatrope 62
5.4.1.3 Norditropin 62
5.4.1.4 Nutropin AQ 63
5.4.1.5 Saizen 64
5.4.1.6 Tev-Tropin/Zomacton/Growject 64
5.4.1.7 Omnitrope Biosimilar 65
5.4.2 Efficacy 68
5.4.2.1 Pediatric GHD 68
5.4.2.2 Adult GHD 68
5.4.3 Safety 69
5.4.3.1 Pediatric GHD 69
5.4.3.2 Adult GHD 69
5.4.4 SWOT Analysis 70
6 Unmet Needs Assessment and Opportunity Analysis 71
6.1 Overview 71
6.2 Improved Adherence and Compliance 72
6.2.1 Unmet Needs 72
6.2.2 Gap Analysis 74
6.2.3 Opportunity 74
6.3 Early Diagnosis 75
6.3.1 Unmet Needs 75
6.3.2 Gap Analysis 75
6.3.3 Opportunity 76
6.4 Disease Awareness and Regulatory Policy in Japan 76
6.4.1 Unmet Needs 76
6.4.2 Gap Analysis 77
6.4.3 Opportunity 77
6.5 Insurance Policies that Impact Patient Access 78
6.5.1 Unmet Needs 78
6.5.2 Gap Analysis 79
6.5.3 Opportunity Analysis 79
6.6 Safer Treatments for Cancer Survivors 79
6.6.1 Unmet needs 79
6.6.2 Gap Analysis 80
6.6.3 Opportunity Analysis 80

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.